Statement: Zantac Litigation - GSK Starts Process for Appeal of Recent Delaware Daubert Decision
June 11, 2024
June 11, 2024
LONDON, England, June 11 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
GSK plc (LSE/NYSE: GSK) today confirms that the Company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court, which permits plaintiff expert testimony as part of the Zantac (ranitidine) litigation in Delaware. GSK strongly disagrees with the Delaware Superior Court's ruling and has filed an application with t . . .
GSK plc (LSE/NYSE: GSK) today confirms that the Company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court, which permits plaintiff expert testimony as part of the Zantac (ranitidine) litigation in Delaware. GSK strongly disagrees with the Delaware Superior Court's ruling and has filed an application with t . . .